DK1912673T3 - Fremgangsmåde til at binde effektor-molekyler til proteiner - Google Patents
Fremgangsmåde til at binde effektor-molekyler til proteinerInfo
- Publication number
- DK1912673T3 DK1912673T3 DK06744294.7T DK06744294T DK1912673T3 DK 1912673 T3 DK1912673 T3 DK 1912673T3 DK 06744294 T DK06744294 T DK 06744294T DK 1912673 T3 DK1912673 T3 DK 1912673T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- effector molecules
- proteins
- binding effector
- cysteines
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 239000012636 effector Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 235000018102 proteins Nutrition 0.000 abstract 4
- 239000003638 chemical reducing agent Substances 0.000 abstract 2
- 235000018417 cysteine Nutrition 0.000 abstract 2
- 150000001945 cysteines Chemical class 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Catalysts (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Jellies, Jams, And Syrups (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0513852.4A GB0513852D0 (en) | 2005-07-06 | 2005-07-06 | Biological products |
PCT/GB2006/002416 WO2007003898A1 (en) | 2005-07-06 | 2006-06-29 | Process for attaching effector molecules to proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1912673T3 true DK1912673T3 (da) | 2011-05-02 |
Family
ID=34856761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06744294.7T DK1912673T3 (da) | 2005-07-06 | 2006-06-29 | Fremgangsmåde til at binde effektor-molekyler til proteiner |
Country Status (15)
Country | Link |
---|---|
US (1) | US8378073B2 (da) |
EP (1) | EP1912673B1 (da) |
JP (1) | JP5203188B2 (da) |
CN (1) | CN101212984B (da) |
AT (1) | ATE502650T1 (da) |
AU (1) | AU2006264684B2 (da) |
CA (1) | CA2613481C (da) |
DE (1) | DE602006020878D1 (da) |
DK (1) | DK1912673T3 (da) |
ES (1) | ES2361096T3 (da) |
GB (1) | GB0513852D0 (da) |
PL (1) | PL1912673T3 (da) |
PT (1) | PT1912673E (da) |
SI (1) | SI1912673T1 (da) |
WO (1) | WO2007003898A1 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009205995B2 (en) * | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
CN102741287B (zh) | 2009-02-17 | 2015-02-18 | Ucb制药公司 | 对人ox40具有特异性的抗体分子 |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
WO2013004844A1 (en) | 2011-07-07 | 2013-01-10 | Novo Nordisk A/S | Drug delivery injection pen with add-on dose capturing and display module |
JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
US11219690B2 (en) | 2013-12-13 | 2022-01-11 | Novo Nordisk Healthcare Ag | Method for thioether conjugation of proteins |
CA3211226A1 (en) * | 2014-02-11 | 2015-08-20 | Seagen Inc. | Selective reduction of proteins |
GB201419184D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins |
US10046058B2 (en) | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
AR103172A1 (es) * | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
SG11201704841UA (en) * | 2014-12-22 | 2017-07-28 | Ucb Biopharma Sprl | Method of protein manufacture |
CN107708679A (zh) | 2015-06-04 | 2018-02-16 | 安特里阿比奥有限公司 | 用于制备位点特异性蛋白质偶联物的胺聚乙二醇化方法 |
CA3052539C (en) * | 2017-02-08 | 2022-08-30 | Pfizer Inc. | Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
MX2023006650A (es) | 2020-12-07 | 2023-06-21 | UCB Biopharma SRL | Anticuerpos multiespecificos y combinaciones de anticuerpos. |
JP2023551983A (ja) | 2020-12-07 | 2023-12-13 | ユーシービー バイオファルマ エスアールエル | インターロイキン-22に対する抗体 |
EP4334355A1 (en) | 2021-05-03 | 2024-03-13 | UCB Biopharma SRL | Antibodies |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4728430A (en) * | 1986-02-10 | 1988-03-01 | Millipore Corporation | Diafiltration method |
US5216183A (en) * | 1988-04-19 | 1993-06-01 | Teijin Limited | Cyclopentanone/cyclopentenone derivative |
US5225194A (en) * | 1989-11-13 | 1993-07-06 | Ldc Research Corporation | Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases |
AU1140495A (en) | 1994-01-27 | 1995-08-03 | Bristol-Myers Squibb Company | Method for preparing thioether conjugates |
US20040121415A1 (en) * | 1996-12-10 | 2004-06-24 | King David John | Monovalent antibody fragments |
GB9625640D0 (en) * | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
DE19911329A1 (de) * | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
AU1604800A (en) * | 1998-10-30 | 2000-05-22 | Nephros, Inc. | Non-isosmotic diafiltration system |
US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
US6406631B1 (en) * | 1999-07-30 | 2002-06-18 | Nephros, Inc. | Two stage diafiltration method and apparatus |
GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
CN1621091A (zh) * | 2003-11-28 | 2005-06-01 | 付经国 | 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法 |
GB0425569D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
US7908694B1 (en) * | 2008-09-24 | 2011-03-22 | Robert Sloane | Mattress cover apparatus with integrated seals |
-
2005
- 2005-07-06 GB GBGB0513852.4A patent/GB0513852D0/en not_active Ceased
-
2006
- 2006-06-29 EP EP06744294A patent/EP1912673B1/en active Active
- 2006-06-29 PT PT06744294T patent/PT1912673E/pt unknown
- 2006-06-29 ES ES06744294T patent/ES2361096T3/es active Active
- 2006-06-29 PL PL06744294T patent/PL1912673T3/pl unknown
- 2006-06-29 DK DK06744294.7T patent/DK1912673T3/da active
- 2006-06-29 DE DE602006020878T patent/DE602006020878D1/de active Active
- 2006-06-29 AT AT06744294T patent/ATE502650T1/de active
- 2006-06-29 SI SI200631002T patent/SI1912673T1/sl unknown
- 2006-06-29 JP JP2008518969A patent/JP5203188B2/ja active Active
- 2006-06-29 WO PCT/GB2006/002416 patent/WO2007003898A1/en active Application Filing
- 2006-06-29 CN CN2006800234116A patent/CN101212984B/zh active Active
- 2006-06-29 AU AU2006264684A patent/AU2006264684B2/en active Active
- 2006-06-29 US US11/994,053 patent/US8378073B2/en active Active
- 2006-06-29 CA CA2613481A patent/CA2613481C/en active Active
Also Published As
Publication number | Publication date |
---|---|
ATE502650T1 (de) | 2011-04-15 |
PT1912673E (pt) | 2011-04-14 |
GB0513852D0 (en) | 2005-08-10 |
AU2006264684B2 (en) | 2011-11-03 |
CN101212984B (zh) | 2011-09-28 |
WO2007003898A1 (en) | 2007-01-11 |
CA2613481A1 (en) | 2007-01-11 |
ES2361096T3 (es) | 2011-06-13 |
JP2008544976A (ja) | 2008-12-11 |
US20080306246A1 (en) | 2008-12-11 |
JP5203188B2 (ja) | 2013-06-05 |
EP1912673B1 (en) | 2011-03-23 |
CA2613481C (en) | 2014-11-25 |
AU2006264684A1 (en) | 2007-01-11 |
WO2007003898A8 (en) | 2008-10-09 |
DE602006020878D1 (de) | 2011-05-05 |
CN101212984A (zh) | 2008-07-02 |
EP1912673A1 (en) | 2008-04-23 |
US8378073B2 (en) | 2013-02-19 |
PL1912673T3 (pl) | 2011-07-29 |
SI1912673T1 (sl) | 2011-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1912673T3 (da) | Fremgangsmåde til at binde effektor-molekyler til proteiner | |
CY1124802T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
ATE517917T1 (de) | Herstellung eines rekombinanten il-18-bindenden proteins | |
WO2008074840A3 (en) | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders | |
MY174493A (en) | Binding agents | |
BRPI0508610A (pt) | derivados de aminoácidos | |
DK1951747T3 (da) | Fremgangsmåde og mellemprodukter til syntese af caspofungin | |
BRPI0515649B8 (pt) | Processo para preparação de composições de anticorpo monoclonal altamente concentradas | |
DE602006010564D1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
EA200802054A1 (ru) | Ингибиторы фермента | |
DE602006009789D1 (de) | Acetylenderivate | |
EA200702193A1 (ru) | Гликозилирование белков | |
NO20082749L (no) | Fremgangsmate for fremstilling av ferri-succinylkasein | |
WO2006079057A3 (en) | Methods and compositions for specific inhibition of protein splicing by small molecules | |
ZA200800862B (en) | Cross-β structure binding compounds | |
DE602006019870D1 (de) | Verfahren zur synthese von triazolen | |
EA200701852A1 (ru) | Производные аминокислот | |
ATE529433T1 (de) | Verfahren zur reinigung eines il-18-bindenden proteins | |
NO20082989L (no) | Fremstiling av gamma-aminosyrer som har affinitet for alfa-2-deltaproteinet | |
WO2009138494A3 (en) | Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors | |
EA200870058A1 (ru) | Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран | |
TW200740769A (en) | Novel process | |
ATE458482T1 (de) | Verwendung von amino substituierten benzimidazolen | |
ITRM20050425A1 (it) | Processo per la produzione di prodotti a base di idrolizzati proteici in composizione con manganese. | |
CY1109747T1 (el) | Μεθοδος διεργασιων για την παρασκευη αναστολεων τρυπτασης |